Cargando…
Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication
BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibod...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578158/ https://www.ncbi.nlm.nih.gov/pubmed/36267253 http://dx.doi.org/10.1093/ofid/ofac493 |
_version_ | 1784811912247115776 |
---|---|
author | Tani, Naoki Ikematsu, Hideyuki Goto, Takeyuki Gondo, Kei Inoue, Takeru Yanagihara, Yuki Kurata, Yasuo Oishi, Ryo Minami, Junya Onozawa, Kyoko Nagano, Sukehisa Kuwano, Hiroyuki Akashi, Koichi Shimono, Nobuyuki Chong, Yong |
author_facet | Tani, Naoki Ikematsu, Hideyuki Goto, Takeyuki Gondo, Kei Inoue, Takeru Yanagihara, Yuki Kurata, Yasuo Oishi, Ryo Minami, Junya Onozawa, Kyoko Nagano, Sukehisa Kuwano, Hiroyuki Akashi, Koichi Shimono, Nobuyuki Chong, Yong |
author_sort | Tani, Naoki |
collection | PubMed |
description | BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. METHODS: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2–naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. RESULTS: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48–6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. CONCLUSIONS: These results suggest an independent correlation between mRNA vaccine–induced specific IgG levels and post–booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers. |
format | Online Article Text |
id | pubmed-9578158 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95781582022-10-19 Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication Tani, Naoki Ikematsu, Hideyuki Goto, Takeyuki Gondo, Kei Inoue, Takeru Yanagihara, Yuki Kurata, Yasuo Oishi, Ryo Minami, Junya Onozawa, Kyoko Nagano, Sukehisa Kuwano, Hiroyuki Akashi, Koichi Shimono, Nobuyuki Chong, Yong Open Forum Infect Dis Major Article BACKGROUND: A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine booster elicits sufficient antibody responses that protect against coronavirus disease 2019, whereas adverse reactions such as fever have been commonly reported. Associations between adverse reactions and antibody responses have not been fully characterized, nor has the influence of antipyretic use. METHODS: This is a prospective observational cohort study in Japan, following our prior investigation of BNT162b2 2-dose primary series. Spike-specific immunoglobulin G (IgG) titers were measured for SARS-CoV-2–naive hospital healthcare workers who received a BNT162b2 booster. The severity of solicited adverse reactions, including the highest body temperature, and self-medicated antipyretics were reported daily for 7 days following vaccination through a web-based self-reporting diary. RESULTS: The data of 281 healthcare workers were available. Multivariate analysis extracted fever after the booster dose (β = .305, P < .001) as being significantly correlated with the specific IgG titers. The analysis of 164 participants with data from the primary series showed that fever after the second dose was associated with the emergence of fever after the booster dose (relative risk, 3.97 [95% confidence interval, 2.48–6.35]); however, the IgG titers after the booster dose were not associated with the presence or degree of fever after the second dose. There were no significant differences in the IgG titers by the use, type, or dosage of antipyretic medication. CONCLUSIONS: These results suggest an independent correlation between mRNA vaccine–induced specific IgG levels and post–booster vaccination fever, without any significant influence of fever after the primary series. Antipyretic medications for adverse reactions should not interfere with the elevation of specific IgG titers. Oxford University Press 2022-09-23 /pmc/articles/PMC9578158/ /pubmed/36267253 http://dx.doi.org/10.1093/ofid/ofac493 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Major Article Tani, Naoki Ikematsu, Hideyuki Goto, Takeyuki Gondo, Kei Inoue, Takeru Yanagihara, Yuki Kurata, Yasuo Oishi, Ryo Minami, Junya Onozawa, Kyoko Nagano, Sukehisa Kuwano, Hiroyuki Akashi, Koichi Shimono, Nobuyuki Chong, Yong Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title | Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title_full | Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title_fullStr | Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title_full_unstemmed | Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title_short | Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication |
title_sort | correlation of postvaccination fever with specific antibody response to severe acute respiratory syndrome coronavirus 2 bnt162b2 booster and no significant influence of antipyretic medication |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578158/ https://www.ncbi.nlm.nih.gov/pubmed/36267253 http://dx.doi.org/10.1093/ofid/ofac493 |
work_keys_str_mv | AT taninaoki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT ikematsuhideyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT gototakeyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT gondokei correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT inouetakeru correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT yanagiharayuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT kuratayasuo correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT oishiryo correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT minamijunya correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT onozawakyoko correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT naganosukehisa correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT kuwanohiroyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT akashikoichi correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT shimononobuyuki correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication AT chongyong correlationofpostvaccinationfeverwithspecificantibodyresponsetosevereacuterespiratorysyndromecoronavirus2bnt162b2boosterandnosignificantinfluenceofantipyreticmedication |